Novartis Oncology Oman
- Re-positioning of Votrient as first choice for Renal Cell Carcinoma in 1st line of treatment in Sultan Qaboos University Hospital and securing this position with advocates there.
- Positioning Votrient as 2nd line of treatment in Soft Tissue Sarcoma patients in Royal Hospital and Sultan Qaboos University Hospital.
- Promoting Sandostatin LAR in whole Oman .
- Recruiting new patients on Sandostatin LAR by Increasing the awareness for NeuroEndocrine Tumor and Acromegaly .
- Forming a Multi Disciplinary Team between the Internal Medicine,Endocrinologist,GastroEnterologist,Onco-Surgeons and Oncologist.
- Removing the obstacles in the NeuroEndocrine Tumor/Acromegaly Patient Journey and proper follow-up on the treatment.